Abstract:The discovery of hybridoma technology, described by Kohler and Milstein in 1975, and the resulting ability to generate monoclonal antibodies (mAbs) initiated a new era in antibody research and clinical development. However, limitations of the hybridoma technology as a routine antibody generation method in conjunction with high immunogenicity responses have led to the development of alternative approaches for the streamlined identification of most effective antibodies. Within this context, display selection technologies such as phage display, ribosome display, yeast display, bacterial display, and mammalian cell surface display have been widely promoted over the past three decades as ideal alternatives to traditional hybridoma methods. The display of antibodies on phages is probably the most widespread and powerful of these methods and, since its invention in late 1980s, significant technological advancements in the design, construction, and selection of antibody libraries have been made, and several fully human antibodies generated by phage display are currently approved or in various clinical development stages. With evolving novel disease targets and the emerging of a new generation of therapeutic antibodies, such as bispecific antibodies, antibody drug conjugates (ADCs), and chimeric antigen receptor T (CAR - T) cell therapies, it is clear that phage display is expected to continue to play a central role in antibody development. Nevertheless, for non-standard and more demanding cases aiming to generate best-in-class therapeutic antibodies against challenging targets and unmet medical needs, in vivo phage display selections by which phage libraries are directly injected into animals or humans for isolating and identifying the phages bound to specific tissues offer an advantage over conventional in vitro phage display screening procedures. Thus, in the present review, we will first summarize a general overview of the antibody therapeutic market, the different types of antibody fragments, and novel engineered variants that have already been explored. Then, we will discuss the state-of-the-art of in vivo phage display methodologies as a promising emerging selection strategy for improvement antibody targeting and drug delivery properties.

Surface‐engineered bacteria in drug development

Bacterial Cell Display for Selection of Affibody Molecules

Redesigning of Microbial Cell Surface and Its Application to Whole-Cell Biocatalysis and Biosensors

Bacterial cell surface characterization by phage display coupled to high-throughput sequencing

In vivo Phage Display: A promising selection strategy for the improvement of antibody targeting and drug delivery properties

Bacterial whole-cell biocatalysts by surface display of enzymes: toward industrial application

Surface nanocoating of bacteria as a versatile platform to develop living therapeutics

Surface-modified bacteria: synthesis, functionalization and biomedical applications

Exploiting Phage Display for Development of Novel Cellular Targeting Strategies

The role of phage display in therapeutic antibody discovery

Bacterial surface display of human lectins in Escherichia coli

Phage display technology and its impact in the discovery of novel protein-based drugs

Advance in phage display technology for bioanalysis.

Progress in Yeast Surface Display System

Display of recombinant proteins at the surface of lactic acid bacteria: strategies and applications

Phage Display in the Quest for New Selective Recognition Elements for Biosensors

Rapid, multiplexed microfluidic phage display.

Mammalian cell display for the discovery and optimization of antibody therapeutics

A novel, non-GMO surface display in Limosilactobacillus fermentum mediated by cell surface hydrolase without anchor motif

Advancements in mammalian display technology for therapeutic antibody development and beyond: current landscape, challenges, and future prospects

Cell surface protein engineering for high-performance whole-cell catalysts